ProtecT trial patients	Patients excluded from the ProtecT	Mortality rates	1502	1700	ProtecT men had a 45% lower risk of death from PCa compared to matched cases (hazard ratio 0.55, 95% confidence interval 0.38–0.83; p = 0.0037), but mortality was similar in those treated radically.
ProtecT trial patients	Patients excluded from the ProtecT	Risk of death from PCa	1502	1646	ProtecT men had a 45% lower risk of death from PCa compared to matched cases (hazard ratio 0.55, 95% confidence interval 0.38–0.83; p = 0.0037),
ProtecT trial patients	Patients excluded from the ProtecT	Rates of radical treatment	13711	13828	There was a similar proportion of men who received radical and nonradical treatments in the matched groups (p = 0.87)
ProtecT trial patients	Patients excluded from the ProtecT	Risk of death from PCa	1502	1645	ProtecT men had a 45% lower risk of death from PCa compared to matched cases (hazard ratio 0.55, 95% confidence interval 0.38–0.83; p = 0.0037)
